Results in line with forecast, page-12

You make some good point worth considering. I am not worried re the fall in next years harvest as all of the harvest figures are transparent hence my estimate of three years to see rocketing prices sharewise. In terms of Santalis it maybe the economics of getting products to the third phase and passing this phase, that is the consideration. There is a risk assessment here in terms of potential capital investment and revenue being affected not to mention losses. Then there is the critical mass/marketing issues with new drugs that larger companies do better with As long as Sandalwood oil is being used in medicine and supermarket products ( the more the merrier by whoever does it ) than I am happy as the oil would come from TFS. The vision was to get create demand at multiple levels. In this case it has been remarkable that in a short time we have had the major essential oils market locked in , now Nestle through acne treatments and the latest of using the oil for wide range of immune system and other disorders. Would be interested in alternative views.